Compile Data Set for Download or QSAR
Report error Found 206 Enz. Inhib. hit(s) with all data for entry = 12962
TargetAdenosine receptor A2a(Human)TBA
LigandPNGBDBM745222(7-methoxy-2- [(1r,2r)-2- phenylcyclopropyl] [1,2,4...)
Affinity DataIC50: 0.100nMAssay Description:Binding affinity using SPA was conducted as follows. Test compounds (50 μL) were dispensed into individual wells of a 384-well OptiPlate™ well (Perki...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetAdenosine receptor A2a(Human)TBA
LigandPNGBDBM745262(2-{cis-3-[4-(1- amino-2,2,2- trifluoroethyl) pheny...)
Affinity DataIC50: 0.300nMAssay Description:Binding affinity using SPA was conducted as follows. Test compounds (50 μL) were dispensed into individual wells of a 384-well OptiPlate™ well (Perki...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetAdenosine receptor A2b(Human)TBA
LigandPNGBDBM745256(2-{3-[5-(2- aminopropan-2- yl)pyridin-2- yl]cyclob...)
Affinity DataIC50: 0.300nMAssay Description:To perform the assay, compounds of the invention to be tested were first solubilized in 100% DMSO and further diluted in 100% DMSO to generate, typic...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetAdenosine receptor A2a(Human)TBA
LigandPNGBDBM745284(7-methoxy-2- (cis-3-{4- [(piperazin-1- yl)methyl]p...)
Affinity DataIC50: 0.300nMAssay Description:Binding affinity using SPA was conducted as follows. Test compounds (50 μL) were dispensed into individual wells of a 384-well OptiPlate™ well (Perki...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetAdenosine receptor A2a(Human)TBA
LigandPNGBDBM50630906(CHEMBL5430246 | US20250171447, Ex-3)
Affinity DataIC50: 0.300nMAssay Description:Binding affinity using SPA was conducted as follows. Test compounds (50 μL) were dispensed into individual wells of a 384-well OptiPlate™ well (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetAdenosine receptor A2b(Human)TBA
LigandPNGBDBM745250(2-{6-[cis-3-(5-amino- 7,9- difluoro[1,2,4]triazolo...)
Affinity DataIC50: 0.400nMAssay Description:To perform the assay, compounds of the invention to be tested were first solubilized in 100% DMSO and further diluted in 100% DMSO to generate, typic...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetAdenosine receptor A2a(Human)TBA
LigandPNGBDBM745192(3-[2-(5-amino-7- methoxy[1,2,4]triazolo [1,5-c]qui...)
Affinity DataIC50: 0.400nMAssay Description:Binding affinity using SPA was conducted as follows. Test compounds (50 μL) were dispensed into individual wells of a 384-well OptiPlate™ well (Perki...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetAdenosine receptor A2a(Human)TBA
LigandPNGBDBM745311(2-{trans-3-[5-(3- aminooxetan-3- yl)-3- methylpyri...)
Affinity DataIC50: 0.400nMAssay Description:Binding affinity using SPA was conducted as follows. Test compounds (50 μL) were dispensed into individual wells of a 384-well OptiPlate™ well (Perki...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetAdenosine receptor A2a(Human)TBA
LigandPNGBDBM745263(2-{cis-3-[4-(1- amino-2,2,2- trifluoroethyl) pheny...)
Affinity DataIC50: 0.5nMAssay Description:Binding affinity using SPA was conducted as follows. Test compounds (50 μL) were dispensed into individual wells of a 384-well OptiPlate™ well (Perki...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetAdenosine receptor A2a(Human)TBA
LigandPNGBDBM745307(3-{6-[trans-3-(5- amino-7- methoxy[1,2,4] triazolo...)
Affinity DataIC50: 0.5nMAssay Description:Binding affinity using SPA was conducted as follows. Test compounds (50 μL) were dispensed into individual wells of a 384-well OptiPlate™ well (Perki...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetAdenosine receptor A2a(Human)TBA
LigandPNGBDBM745193(N-{3-[2-(5-amino-7- methoxy[1,2,4]triazolo [1,5-c]...)
Affinity DataIC50: 0.5nMAssay Description:Binding affinity using SPA was conducted as follows. Test compounds (50 μL) were dispensed into individual wells of a 384-well OptiPlate™ well (Perki...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetAdenosine receptor A2a(Human)TBA
LigandPNGBDBM745277(US20250171447, Ex-90)
Affinity DataIC50: 0.600nMAssay Description:Binding affinity using SPA was conducted as follows. Test compounds (50 μL) were dispensed into individual wells of a 384-well OptiPlate™ well (Perki...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetAdenosine receptor A2a(Human)TBA
LigandPNGBDBM745227(9-fluoro-2-[2-fluoro-2- phenylcyclopropyl]-7- meth...)
Affinity DataIC50: 0.600nMAssay Description:Binding affinity using SPA was conducted as follows. Test compounds (50 μL) were dispensed into individual wells of a 384-well OptiPlate™ well (Perki...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetAdenosine receptor A2a(Human)TBA
LigandPNGBDBM745286(7-methoxy-2- (cis-3-{4-[(2R)- 2-(trifluoromethyl) ...)
Affinity DataIC50: 0.600nMAssay Description:Binding affinity using SPA was conducted as follows. Test compounds (50 μL) were dispensed into individual wells of a 384-well OptiPlate™ well (Perki...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetAdenosine receptor A2a(Human)TBA
LigandPNGBDBM50630909(CHEMBL5413371 | US20250171447, Ex-83)
Affinity DataIC50: 0.600nMAssay Description:Binding affinity using SPA was conducted as follows. Test compounds (50 μL) were dispensed into individual wells of a 384-well OptiPlate™ well (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetAdenosine receptor A2a(Human)TBA
LigandPNGBDBM745230(US20250171447, Ex-42)
Affinity DataIC50: 0.600nMAssay Description:Binding affinity using SPA was conducted as follows. Test compounds (50 μL) were dispensed into individual wells of a 384-well OptiPlate™ well (Perki...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetAdenosine receptor A2a(Human)TBA
LigandPNGBDBM745288(7-methoxy-2- (cis-3-{5- methyl-6-[(3R)- 3-methylpi...)
Affinity DataIC50: 0.700nMAssay Description:Binding affinity using SPA was conducted as follows. Test compounds (50 μL) were dispensed into individual wells of a 384-well OptiPlate™ well (Perki...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetAdenosine receptor A2b(Human)TBA
LigandPNGBDBM745331(US20250171447, Ex-144)
Affinity DataIC50: 0.800nMAssay Description:To perform the assay, compounds of the invention to be tested were first solubilized in 100% DMSO and further diluted in 100% DMSO to generate, typic...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetAdenosine receptor A2a(Human)TBA
LigandPNGBDBM745274(2-{3-[5-(2- aminopropan-2- yl)-3- chloropyridin-2-...)
Affinity DataIC50: 0.800nMAssay Description:Binding affinity using SPA was conducted as follows. Test compounds (50 μL) were dispensed into individual wells of a 384-well OptiPlate™ well (Perki...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetAdenosine receptor A2a(Human)TBA
LigandPNGBDBM745194(6-[2-(5-amino-7- methoxy[1,2,4]triazolo [1,5-c]qui...)
Affinity DataIC50: 0.900nMAssay Description:Binding affinity using SPA was conducted as follows. Test compounds (50 μL) were dispensed into individual wells of a 384-well OptiPlate™ well (Perki...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetAdenosine receptor A2a(Human)TBA
LigandPNGBDBM745238(2-{4-[cis-3-(5-amino- 9-fluoro-7- methoxy [1,2,4]t...)
Affinity DataIC50: 1nMAssay Description:Binding affinity using SPA was conducted as follows. Test compounds (50 μL) were dispensed into individual wells of a 384-well OptiPlate™ well (Perki...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetAdenosine receptor A2a(Human)TBA
LigandPNGBDBM745290(1-{6-[trans-3-(5- amino-7- methoxy[1,2,4] triazolo...)
Affinity DataIC50: 1.10nMAssay Description:Binding affinity using SPA was conducted as follows. Test compounds (50 μL) were dispensed into individual wells of a 384-well OptiPlate™ well (Perki...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetAdenosine receptor A2a(Human)TBA
LigandPNGBDBM50630907(CHEMBL5413330 | US20250171447, Ex-38)
Affinity DataIC50: 1.10nMAssay Description:Binding affinity using SPA was conducted as follows. Test compounds (50 μL) were dispensed into individual wells of a 384-well OptiPlate™ well (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetAdenosine receptor A2a(Human)TBA
LigandPNGBDBM745241(2-{5-[cis-3-(5-amino-7- methoxy [1,2,4]triazolo [1...)
Affinity DataIC50: 1.10nMAssay Description:Binding affinity using SPA was conducted as follows. Test compounds (50 μL) were dispensed into individual wells of a 384-well OptiPlate™ well (Perki...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetAdenosine receptor A2a(Human)TBA
LigandPNGBDBM745278(2-{(1s,3s)-3-[6- (2-amino-1,1- difluoropropan- 2-y...)
Affinity DataIC50: 1.10nMAssay Description:Binding affinity using SPA was conducted as follows. Test compounds (50 μL) were dispensed into individual wells of a 384-well OptiPlate™ well (Perki...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetAdenosine receptor A2a(Human)TBA
LigandPNGBDBM745236(2-{6-[cis-3-(5-amino-7- methoxy [1,2,4]triazolo [1...)
Affinity DataIC50: 1.20nMAssay Description:Binding affinity using SPA was conducted as follows. Test compounds (50 μL) were dispensed into individual wells of a 384-well OptiPlate™ well (Perki...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetAdenosine receptor A2a(Human)TBA
LigandPNGBDBM745264(2-(trans-3-{5- [(1S)-1-amino- 2,2,2- trifluoroethy...)
Affinity DataIC50: 1.30nMAssay Description:Binding affinity using SPA was conducted as follows. Test compounds (50 μL) were dispensed into individual wells of a 384-well OptiPlate™ well (Perki...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetAdenosine receptor A2a(Human)TBA
LigandPNGBDBM745195(7-methoxy-2-[2-(7- methylimidazo[1,2-alpyridin-6- ...)
Affinity DataIC50: 1.30nMAssay Description:Binding affinity using SPA was conducted as follows. Test compounds (50 μL) were dispensed into individual wells of a 384-well OptiPlate™ well (Perki...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetAdenosine receptor A2a(Human)TBA
LigandPNGBDBM50630908(CHEMBL5426841 | US20250171447, Ex-49)
Affinity DataIC50: 1.30nMAssay Description:Binding affinity using SPA was conducted as follows. Test compounds (50 μL) were dispensed into individual wells of a 384-well OptiPlate™ well (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetAdenosine receptor A2b(Human)TBA
LigandPNGBDBM745272(2-{trans-3-[5-(2- aminopropan-2- yl)-3- fluoropyri...)
Affinity DataIC50: 1.30nMAssay Description:To perform the assay, compounds of the invention to be tested were first solubilized in 100% DMSO and further diluted in 100% DMSO to generate, typic...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetAdenosine receptor A2a(Human)TBA
LigandPNGBDBM745301(7-methoxy-2- {trans-3-[6-(4- methylpiperazin- 1-yl...)
Affinity DataIC50: 1.30nMAssay Description:Binding affinity using SPA was conducted as follows. Test compounds (50 μL) were dispensed into individual wells of a 384-well OptiPlate™ well (Perki...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetAdenosine receptor A2a(Human)TBA
LigandPNGBDBM745228(US20250171447, Ex-40)
Affinity DataIC50: 1.40nMAssay Description:Binding affinity using SPA was conducted as follows. Test compounds (50 μL) were dispensed into individual wells of a 384-well OptiPlate™ well (Perki...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetAdenosine receptor A2a(Human)TBA
LigandPNGBDBM745331(US20250171447, Ex-144)
Affinity DataIC50: 1.40nMAssay Description:Binding affinity using SPA was conducted as follows. Test compounds (50 μL) were dispensed into individual wells of a 384-well OptiPlate™ well (Perki...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetAdenosine receptor A2a(Human)TBA
LigandPNGBDBM745196(5-[2-(5-amino-7- methoxy[1,2,4]triazolo [1,5-c]qui...)
Affinity DataIC50: 1.5nMAssay Description:Binding affinity using SPA was conducted as follows. Test compounds (50 μL) were dispensed into individual wells of a 384-well OptiPlate™ well (Perki...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetAdenosine receptor A2a(Human)TBA
LigandPNGBDBM745289(7-methoxy-2- (trans-3-{5- methyl-6-[(3R)- 3-methyl...)
Affinity DataIC50: 1.5nMAssay Description:Binding affinity using SPA was conducted as follows. Test compounds (50 μL) were dispensed into individual wells of a 384-well OptiPlate™ well (Perki...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetAdenosine receptor A2a(Human)TBA
LigandPNGBDBM745216(US20250171447, Ex-28)
Affinity DataIC50: 1.5nMAssay Description:Binding affinity using SPA was conducted as follows. Test compounds (50 μL) were dispensed into individual wells of a 384-well OptiPlate™ well (Perki...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetAdenosine receptor A2a(Human)TBA
LigandPNGBDBM745285(7-methoxy-2- (trans-3-{4- [(piperazin-1- yl)methyl...)
Affinity DataIC50: 1.60nMAssay Description:Binding affinity using SPA was conducted as follows. Test compounds (50 μL) were dispensed into individual wells of a 384-well OptiPlate™ well (Perki...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetAdenosine receptor A2b(Human)TBA
LigandPNGBDBM50630909(CHEMBL5413371 | US20250171447, Ex-83)
Affinity DataIC50: 1.60nMAssay Description:To perform the assay, compounds of the invention to be tested were first solubilized in 100% DMSO and further diluted in 100% DMSO to generate, typic...More data for this Ligand-Target Pair
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetAdenosine receptor A2a(Human)TBA
LigandPNGBDBM745233(2-{6-[cis-3-(5-amino- 9-fluoro-7- methoxy [1,2,4]t...)
Affinity DataIC50: 1.60nMAssay Description:Binding affinity using SPA was conducted as follows. Test compounds (50 μL) were dispensed into individual wells of a 384-well OptiPlate™ well (Perki...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetAdenosine receptor A2b(Human)TBA
LigandPNGBDBM745251(2-{6-[trans-3-(5- amino-7,9- difluoro[1,2,4]triazo...)
Affinity DataIC50: 1.70nMAssay Description:To perform the assay, compounds of the invention to be tested were first solubilized in 100% DMSO and further diluted in 100% DMSO to generate, typic...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetAdenosine receptor A2a(Human)TBA
LigandPNGBDBM745302(7-methoxy-2- {cis-3-[6-(4- methylpiperazin- 1-yl)p...)
Affinity DataIC50: 1.70nMAssay Description:Binding affinity using SPA was conducted as follows. Test compounds (50 μL) were dispensed into individual wells of a 384-well OptiPlate™ well (Perki...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetAdenosine receptor A2a(Human)TBA
LigandPNGBDBM745306(3-{6-[cis-3-(5- amino-7- methoxy[1,2,4] triazolo[1...)
Affinity DataIC50: 1.80nMAssay Description:Binding affinity using SPA was conducted as follows. Test compounds (50 μL) were dispensed into individual wells of a 384-well OptiPlate™ well (Perki...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetAdenosine receptor A2b(Human)TBA
LigandPNGBDBM745254(US20250171447, Ex-67)
Affinity DataIC50: 1.80nMAssay Description:To perform the assay, compounds of the invention to be tested were first solubilized in 100% DMSO and further diluted in 100% DMSO to generate, typic...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetAdenosine receptor A2a(Human)TBA
LigandPNGBDBM745310(2-{cis-3-[5-(3- aminooxetan-3- yl)-3- methylpyridi...)
Affinity DataIC50: 1.80nMAssay Description:Binding affinity using SPA was conducted as follows. Test compounds (50 μL) were dispensed into individual wells of a 384-well OptiPlate™ well (Perki...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetAdenosine receptor A2a(Human)TBA
LigandPNGBDBM745265(2-(cis-3-{5- [(1S)-1-amino- 2,2,2- trifluoroethyl]...)
Affinity DataIC50: 1.90nMAssay Description:Binding affinity using SPA was conducted as follows. Test compounds (50 μL) were dispensed into individual wells of a 384-well OptiPlate™ well (Perki...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetAdenosine receptor A2a(Human)TBA
LigandPNGBDBM745255(US20250171447, Ex-68)
Affinity DataIC50: 2nMAssay Description:Binding affinity using SPA was conducted as follows. Test compounds (50 μL) were dispensed into individual wells of a 384-well OptiPlate™ well (Perki...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetAdenosine receptor A2a(Human)TBA
LigandPNGBDBM745253(1-{6-[trans-3-(5- amino-7- methoxy [1,2,4]triazolo...)
Affinity DataIC50: 2nMAssay Description:Binding affinity using SPA was conducted as follows. Test compounds (50 μL) were dispensed into individual wells of a 384-well OptiPlate™ well (Perki...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetAdenosine receptor A2a(Human)TBA
LigandPNGBDBM745197(7-methoxy-2-[2-(3- methyl[1,2,4]triazolo [4,3-a]py...)
Affinity DataIC50: 2nMAssay Description:Binding affinity using SPA was conducted as follows. Test compounds (50 μL) were dispensed into individual wells of a 384-well OptiPlate™ well (Perki...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetAdenosine receptor A2b(Human)TBA
LigandPNGBDBM745324(US20250171447, Ex-137)
Affinity DataIC50: 2.10nMAssay Description:To perform the assay, compounds of the invention to be tested were first solubilized in 100% DMSO and further diluted in 100% DMSO to generate, typic...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetAdenosine receptor A2a(Human)TBA
LigandPNGBDBM745252(1-{6-[cis-3-(5-amino-7- methoxy [1,2,4]triazolo [1...)
Affinity DataIC50: 2.10nMAssay Description:Binding affinity using SPA was conducted as follows. Test compounds (50 μL) were dispensed into individual wells of a 384-well OptiPlate™ well (Perki...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
TBA
Entry Details
US Patent

Displayed 1 to 50 (of 206 total ) | Next | Last >>
Jump to: